Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH

a week ago

Outcomes is the third study in the Phase 3 SYNCHRONY clinical trial program ...

Ticker	Sentiment	Impact
AKRO	Neutral	11 %